Products for Research Use Only

Pomalidomide-d4

CAT: 0804-HY-10984S2Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10984S2Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Pomalidomide-d4 is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors<
CAS Number
1416575-78-4
Product Name Alternative
CC-4047-d4
UNSPSC
12352005
Hazard Statement
H360
Target
Apoptosis; Isotope-Labeled Compounds; Ligands for E3 Ligase; Molecular Glues
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis; Others; PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
96.38
Solubility
10 mM in DMSO
Smiles
O=C1N(C2C(NC(C([2H])([2H])C2([2H])[2H])=O)=O)C(C3=C(N)C=CC=C31)=O
Molecular Formula
C13H7D4N3O4
Molecular Weight
277.27
Precautions
H360
References & Citations
[1]Zhu YX, et al. Molecular mechanism of action of the immune-modulatory drugs, thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013 Apr;54 (4) :683-7.; Hernandez-Ilizaliturri FJ1, et al. Immunomodulatory drug CC-5013 or CC-4047 a|[2]Hernandez-Ilizaliturri FJ, et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005 Aug 15;11 (16) :5984-92.|[3]Yuan Xiao Zhu, et al. Molecular mechanism of action of the immune-modulatory drugs, thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013 Apr;54 (4) :683-7.; Hernandez-Ilizaliturri FJ1
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Isoform
Cereblon